Onsdag 2 April | 13:37:13 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-07-15 08:00 Kvartalsrapport 2025-Q2
2025-05-28 N/A X-dag ordinarie utdelning BONEX 0.00 SEK
2025-05-27 N/A Årsstämma
2025-04-24 08:00 Kvartalsrapport 2025-Q1
2025-02-25 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-07-11 - Kvartalsrapport 2024-Q2
2024-05-17 - X-dag ordinarie utdelning BONEX 0.00 SEK
2024-05-16 - Årsstämma
2024-04-25 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-07-13 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning BONEX 0.00 SEK
2023-05-17 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning BONEX 0.00 SEK
2022-05-19 - Årsstämma
2022-05-04 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-05-21 - X-dag ordinarie utdelning BONEX 0.00 SEK
2021-05-20 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-05-20 - X-dag ordinarie utdelning BONEX 0.00 SEK
2020-05-19 - Årsstämma
2020-05-08 - Kvartalsrapport 2020-Q1
2020-02-26 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-07-25 - Kvartalsrapport 2019-Q2
2019-05-15 - X-dag ordinarie utdelning BONEX 0.00 SEK
2019-05-14 - Årsstämma
2019-05-02 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-07 - Kvartalsrapport 2018-Q3
2018-07-26 - Kvartalsrapport 2018-Q2
2018-05-23 - X-dag ordinarie utdelning BONEX 0.00 SEK
2018-05-22 - Årsstämma
2018-05-04 - Kvartalsrapport 2018-Q1
2018-02-20 - Bokslutskommuniké 2017
2017-11-02 - Kvartalsrapport 2017-Q3
2017-08-17 - Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Bonesupport är verksamt inom medicinteknikbranschen och fokuserar på utveckling och tillverkning av biokeramiska implantat för benreparation och rekonstruktion. Bolagets produkter riktar sig till kirurger och sjukvårdsinstitutioner. Verksamheten är global med en huvudsaklig närvaro i Europa, Nordamerika och Asien. Bonesupport grundades 1999 och har sitt huvudkontor i Lund, Sverige.
2025-02-25 08:00:00

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the year end report for the fourth quarter 2024 and full year 2024.

THE GROWTH JOURNEY CONTINUES, STRONG CASH FLOW

"Strong sales growth, record results and groundbreaking clinical outcomes." Emil Billbäck, CEO

OCTOBER - DECEMBER 2024

  • Net sales increased by 49 percent (48 percent at constant exchange rates) and amounted to SEK 257.0 million (172.7).
  • The North America (NA) segment reported a sales growth of 59 percent (58 percent at constant exchange rate).
  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 16 percent (17 percent at constant exchange rates).
  • The gross margin amounted to 92.6 percent (91.8).
  • The operating result before effects from the Group’s incentive programs amounted to SEK 78.0 million (11.2). The reported operating result amounted to SEK 64.2 million (-7.7).
  • Earnings per share before dilution were SEK 0.82 (0.16).
  • Earnings per share after dilution were SEK 0.81 (0.16).

JANUARY - DECEMBER 2024

  • Net sales increased by 52 percent (52 percent at constant exchange rates) and amounted to SEK 898.7 million (591.1).
  • The North America (NA) segment reported a sales growth of 62 percent (63 percent at constant exchange rate).
  • The Europe & Rest of the World (EUROW) segment reported a sales growth of 23 percent (22 percent at constant exchange rates).
  • The gross margin amounted to 92.6 percent (91.5)
  • The operating result before effects from the Group’s incentive programs amounted to SEK 203.9 million (54.1). The reported operating result amounted to SEK 166.1 million (13.9).
  • Earnings per share before dilution were SEK 2.04 (3.77).
  • Earnings per share after dilution were SEK 2.01 (3.74).
  • Adjusted for deferred tax receivables on tax losses carried forward, which were reported for the first time during the comparison period, the earnings per share before and after dilution were SEK 0.12 during the comparison period.
  • The Board proposed that no dividend be paid for the financial year 2024.


EVENTS DURING THE PERIOD
During the fourth quarter, in accordance with the decision made at the Annual General Meeting in May 2024, the Board of BONESUPPORT decided to utilize the authorization to enter into a share swap agreement with the Company’s bank with the purpose of securing the Company’s delivery of performance shares to the participants in the Long Term Incentive program that the Annual General Meeting had decided to implement. The swap amounted to SEK 68.7 million.

EVENTS AFTER THE PERIOD
In January 2025, a clinical study including 105 diabetes patients with bone infection in the foot, was reported, that showed that treatment with CERAMENT G or CERAMENT V gave significant advantages compared to standard treatment. The results showed improved infection healing and a dramatic improvement in survival rate to 87.5 percent compared to 44.9 percent in the standard treatment group, over a five year period.